Oryzon Genomics S.A.
A clinical-stage biopharma developing epigenetic therapies for cancer and CNS disorders.
ORY | MC
Overview
Corporate Details
- ISIN(s):
- ES0167733015
- LEI:
- 95980063R15RDF29DK13
- Country:
- Spain
- Address:
- Sant Ferran 74, 08940 Cornellà de Llobregat
- Website:
- https://www.oryzon.com/en
- Sector:
- Manufacturing
Description
Oryzon Genomics is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on epigenetics. The company's primary focus is on creating personalized medicines for patients with cancer and central nervous system (CNS) disorders. Utilizing a proprietary epigenetic platform, Oryzon identifies and validates biomarkers and therapeutic targets to advance its pipeline of potential treatments. The company's therapeutic programs aim to address diseases with significant unmet medical needs by regulating gene expression without altering the underlying genetic sequence.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-06-10 07:51 |
ORYZON presenta nuevos datos positivos de eficacia de iadademstat de su ensayo …
|
Spanish | 327.9 KB | ||
| 2022-06-08 07:58 |
ORYZON recibe la aprobación de la FDA para la designación de medicamento huérfa…
|
Spanish | 285.5 KB | ||
| 2022-05-23 12:53 |
Convocatoria de la Junta General Ordinaria de accionistas de Oryzon Genomics, S…
|
Spanish | 222.5 KB | ||
| 2022-05-05 18:04 |
La Sociedad remite información sobre los resultados del primer trimestre del añ…
|
Spanish | 360.5 KB | ||
| 2022-03-21 07:43 |
ORYZON recibe la autorización de la FDA para su IND para realizar FRIDA, un ens…
|
Spanish | 375.4 KB | ||
| 2022-02-07 08:53 |
La Sociedad remite el Informe Anual sobre remuneraciones de los consejeros del …
|
Spanish | 185.3 KB | ||
| 2022-02-07 00:00 |
Corporate Governance Report - Oryzon Genomics S.A.
|
Spanish | 185.3 KB | ||
| 2022-02-07 00:00 | Spanish | 3.0 MB | |||
| 2022-01-04 08:00 |
ORYZON recibe la autorización para iniciar el brazo serbio de PORTICO, un ensay…
|
Spanish | 138.0 KB | ||
| 2021-12-13 08:05 |
ORYZON presenta nuevos datos positivos de eficacia de iadademstat de su ensayo …
|
Spanish | 324.0 KB | ||
| 2021-10-28 17:44 |
La sociedad remite información sobre los resultados del tercer trimestre de 2021
|
Spanish | 410.7 KB | ||
| 2021-10-13 08:04 |
ORYZON presenta datos de seguridad y eficacia de vafidemstat del ensayo clínico…
|
Spanish | 241.9 KB | ||
| 2021-07-13 08:07 |
ORYZON recibe la aprobación de la Agencia Española del Medicamento y Productos …
|
Spanish | 296.7 KB | ||
| 2021-07-09 08:01 |
ORYZON presenta datos preliminares del ensayo de Fase II ESCAPE de vafidemstat …
|
Spanish | 340.7 KB | ||
| 2021-06-15 07:54 |
ORYZON obtiene la aprobación por la FDA del IND para PORTICO, un ensayo clínico…
|
Spanish | 325.4 KB |
Automate Your Workflow. Get a real-time feed of all Oryzon Genomics S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Oryzon Genomics S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Oryzon Genomics S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
